Kornimate/medical-research-clean huggingface dataset:
determinants of balance in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the primary aim of our study is to examine the relationship between balance and respiratory function, respiratory and peripheral muscle strength, functional capacity, and cognitive function in patients with chronic obstructive pulmonary disease (copd). the secondary aim of our study is to compare respiratory function, respiratory and peripheral muscle strength, functional capacity, balance, and cognitive functions of copd patients and healthy individuals. this study will examine and record the participant's sociodemographic information and medical records. balance, respiratory function, respiratory and peripheral muscle strength, functional capacity, and cognitive function will be assessed. since the patients are included in this study, no intervention will be made, no additional tests will be performed, or no changes will be made in the routine treatments of the patients during the study.


Eligibility criteria:
copd group inclusion criteria: * being diagnosed with copd in accordance with the gold criteria * being between the ages of 40-65 * to be able to speak, read, understand, and cooperate in turkish * being a volunteer to participate in the study copd group exclusion criteria: * having a copd exacerbation in the last 8 weeks and/or having an unstable clinical condition * having a diagnosed vision, hearing, or neurological disease that may affect balance * having any other neurological, orthopedic, cardiovascular, thoracic, or metabolic disease or pathological condition that would affect assessments * resting saturation below 90% during exercise tests * being on long-term oxygen therapy control group inclusion criteria: * being between the ages of 40-65 * to be able to speak, read, understand, and cooperate in turkish * being a volunteer to participate in the study control group exclusion criteria: * having a diagnosed vision, hearing, or neurological disease that may affect balance * having any other neurological, orthopedic, cardiovascular, thoracic, or metabolic disease or pathological condition that would affect assessments * resting saturation below 90% during exercise tests
correction of vitamin d inadequacy in nursing home residents

Conditions: Hypovitaminosis D

Summary: vitamin d inadequacy continues to be neglected in nursing home residents. we hypothesized that part of this neglect is due to absence of data documenting safe and effective ways to replete this inadequacy.

vitamin d inadequacy continues to be neglected in nursing home residents. we hypothesized that part of this neglect is due to absence of data documenting safe and effective ways to replete this inadequacy. subjects with low vitamin d concentrations are dosed with 50.000 iu three times a week for 25 hydroxy vitamin d, parathyroid hormone and bone turnover status. .

Eligibility criteria:
inclusion criteria: * able to walk * reside in nursing home for the 12 weeks of study exclusion criteria: * non-ambulatory residents
gait analysis by induced disorientation in a vr environment

Conditions: Mild Cognitive Impairment; Mild Dementia; Disorientation; Young Adults; Older Adults

Summary: the aim of the study is to investigate whether the effect of disorientation on physical motion and gait among dementia patients, can be reliably measured in a laboratory environment, by means of a virtual reality (vr) experimental setup.

challenges in wayfinding and orientation are early symptoms of mci and dementia. these deficits decrease mobility which again leads to further cognitive decline. in a field study, we developed a pattern recognition model of disorientated behaviour based on accelerometric data. however, it is questionable if phases of disorientation also affect gait parameters. furthermore, there is growing evidence that impaired cognitive functioning is associated with changes in gait performance, e.g. gait variability, measured in dual-task walking conditions. increases in heart rate and skin conductance have also been reported during instances of disorientation. hence, we implemented a 3d environment of a familiar city centre in the grail, which combines a fully instrumented treadmill with a synchronized vr environment. we record gait parameters through the motion capture system, and accelerometric and physiological data using wearable sensors (movisens), for comparability with the sindem field study. young and old healthy adults will participate in the first phase of the study, while mild dementia or mci patients will participate in the later phases. phases of disorientation will be induced by changing the virtual environment.we aim to assess gait, accelerometric and physiological parameters during instances of disorientation, using the grail (gait real-time analysis interactive lab, motekforce link). the results will further enable the automatic detection of disorientation based on gait parameters, physiological and accelerometric data. this is necessary for the development of a situation-aware assistive system which supports persons with dementia in autonomous outdoor mobility.

Eligibility criteria:
inclusion criteria: * within the required age bracket * mobile * dementia exclusion criteria: * other neurological conditions besides dementia * inability to understand task instructions, deaf-mute, blindness
enhancing adaptations to exercise

Conditions: Inflammation

Summary: researchers are trying to understand how chronic inflammation affects muscle function and responses to exercise.they are also trying to determine if suppressing chronic inflammation using omega-3 fatty acids (n3-pufa) restores skeletal muscle function and exercise responsiveness in older adults.

participants will be divided into two groups. men and women between the ages of 20-35 years and 65-85 years. participants in the older age group will be randomly assigned to receive groups (n3-pufa or placebo (soybean oil)) in a double-blind manner. before and after the intervention, all participants will complete an outpatient study day (body composition, blood draw, treadmill test, strength test) and an inpatient study day (muscle biopsies, fat biopsies, indirect calorimetry, exercise test, mixed meal test). during the intervention phase of the study, participants will be instructed to swallow 2 softgels twice per day with meals (morning and evening) for a total of 4 softgels per day. every 4 weeks, participants will report to the clinical research and trials unit (crtu) to pick up a new prescription and return any remaining capsules from the previous prescription. on the day they pick up prescription refills, participants will report to the crtu for a fasting blood sample. the duration of the intervention will be 6 months.

Eligibility criteria:
inclusion criteria: * men and women between the ages of 20-35 years * men and women between the ages of 65-85 years exclusion criteria: * regular use of omega-3 nutritional supplements * diabetes or fasting plasma glucose \> or equal to 126 mg/dl * anemia (female subjects hemoglobin of \<11 g/dl and male subjects hemoglobin \<12 g/dl) * active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment) * renal failure (serum creatinine \> 1.5mg/dl) * chronic active liver disease (ast\>144 iu/l or alt\>165 iu/l) * oral warfarin group medications or history of blood clotting disorders. * international normalized ratio (inr) \>2.01.5 * smoking * pregnancy or breastfeeding * alcohol consumption greater than 2 glasses/day or other substance abuse * untreated or uncontrolled hypothyroidism * debilitating chronic disease (at the discretion of the investigators) * fish or shellfish allergy

Keywords: exercise muscle function
effect of probiotic lacobacillus reuterii on serum bilirubin levels in preterm infants

Conditions: Hyperbilirubinemia, Neonatal

Summary: the goal of this clinical trial is to learn about the effect of probiotic lactobacillus reuterii on the level of serum bilirubin in moderately and late preterm infants with birth weights 1000 grams to 2499 grams who were admitted to the nicu at dr. wahidin sudirohusodo hospital, hasanuddin university hospital and cahaya medika hospital. the main questions it aims to answer are: * are bilirubin levels in preterm infants who received probiotics were lower than those who did not receive probiotics? * is the incidence of hyperbilirubinemia requiring phototherapy in preterm infants who received probiotics less than those who did not receive probiotics?

this study aims to investigate the effect of probiotic lactobacillus reuteri administration on serum bilirubin levels in preterm infants. it is a randomized controlled trial conducted at the neonatal intensive care units of dr. wahidin sudirohusodo hospital, hasanuddin university hospital and cahaya medika hospital in makassar, south sulawesi, indonesia. the study population includes infants born at 32 to \<37 weeks gestational age with birth weights between 1000-2499 grams who are admitted to the nicu. eligible infants are randomized into two groups - an intervention group receiving probiotic l. reuteri (5 drops daily for 7 days) and a control group not receiving probiotics. the primary outcome is serum bilirubin levels, measured at baseline and after 7 days of intervention. secondary outcomes include incidence of hyperbilirubinemia requiring phototherapy and changes in bilirubin levels in those receiving phototherapy. blood samples are collected to measure total and direct bilirubin levels. the study aims to enroll 40 infants (20 per group) to detect a clinically meaningful difference in bilirubin levels between groups. this trial will provide evidence on whether probiotic supplementation with l. reuteri can reduce the severity of hyperbilirubinemia in preterm infants. the results may inform clinical practice regarding the use of probiotics as an adjunctive therapy for neonatal jaundice in this vulnerable population.

Eligibility criteria:
inclusion criteria: * premature infants (32 - \< 37 weeks gestation) * birth weight 1000 - 2499 grams * sick infants who are treated in the nicu * preterm infants who received enteral feeding \> 30 cc/kgbb less than 72 hours after birth, without jaundice or jaundice kremer 1,2, and 3 * parents have signed their child's consent to participate in the study exclusion criteria: * infants with multiple congenital abnormalities * infants with jaundice before 24 hours or having jaundice cremer \> 4 less than 72 hours from birth * infants with sepsis, metabolic acidosis

Keywords: hyperbilirubinemia probiotic lactobacillus reuterii
prospective clinical trial of hiv+ living donor kidney donation for hiv+ recipients

Conditions: HIV Infections

Summary: prospective clinical trial of hiv+ living donor kidney donation for hiv+ recipients

this is a prospective study to evaluate the safety of donor nephrectomy in hiv+ individuals who donate kidneys to hiv+ candidates in need of transplant . the study will assess potential complications of hiv + living donors - including adverse events related to nephrectomy, development of chronic kidney disease, hypertension, and hiv-related complications.

Eligibility criteria:
inclusion criteria: * able to understand and provide consent * age 21 years or older * meets standard clinical criteria for living donation per johns hopkins university (jhu) comprehensive transplant center policy * documented hiv infection (by any licensed enzyme-linked immunosorbent assay (elisa) and confirmation by western blot, positive hiv ab immunofluorescent assay (ifa), or documented history of detectable hiv-1 rna) * cd4+ t-cell count ≥ 500/µl for 6 months prior to donation * hiv-1 rna below 50 copies rna/ml (viral blips between 50-400 copies will be allowed as long as there are not consecutive measurements \>200 copies/ml) exclusion criteria: * two high risk alleles of apol1 (g1 or g2 variants) * hypertension * diabetes * chronic active hepatitis c (detectable hcv rna in plasma) * evidence of invasive opportunistic complications from hiv infection * mentally incompetent and/or inability to provide informed consent * other medical conditions, as determined by the provider, that would preclude donation
study to evaluate the effect of gbt440 in pediatrics with sickle cell disease

Conditions: Sickle Cell Disease

Summary: this study consists of four parts, parts a, b, c, and d. * part a is a single dose pharmacokinetic (pk) study in pediatric participants with sickle cell disease ages 6 to 17 years. * part b is a multiple dose, safety, exploratory, efficacy, and pk study in adolescent participants with sickle cell disease ages 12 to 17 years. * part c is a multiple dose, safety, tolerability, and pk study, which includes the assessment of hematological effects and the effect on tcd flow velocity of voxelotor in pediatric participants with sickle cell disease ages 4 to 17 years. * part d is a multiple dose, safety, tolerability, and pk study, which examines the hematological effects of voxelotor in pediatric participants with sickle cell disease ages 6 months to \< 4 years.


Eligibility criteria:
inclusion criteria: * male or female participants with homozygous hemoglobin ss (hbss) or hemoglobin s beta0 thalassemia (hbs β0thal) * age: * part a - 6 to 17 years of age * part b - 12 to 17 years of age * part c - 4 to 17 years of age * part d - 6 months to \<4 years of age * hydroxyurea (hu) therapy: * parts a, b, and c: a participant taking hydroxyurea (hu) may be enrolled if the dose has been stable for at least 3 months with no anticipated need for dose adjustment during the study and no sign of hematological toxicity. * part d: a participant taking hu may be enrolled if the dose has been stable for at least 1 month. titration to the maximum tolerated dose (mtd) is allowed during the study. * hemoglobin (hb): * part a - no restriction * parts b, c, \& d - hb ≤ 10.5 g/dl * for part c only: participants 12 to 17 years of age must have a tcd velocity of ≥ 140 cm/sec measured anytime during screening. exclusion criteria: * any one of the following requiring medical attention within 14 days of signing the informed consent form (icf): * vaso-occlusive crisis (voc) * acute chest syndrome (acs) * splenic sequestration crisis * dactylitis * requires chronic transfusion therapy * history of stroke or meeting criteria for primary stroke prophylaxis (history of two tcd measurements ≥ 200 cm/sec by non-imaging tcd or ≥185 cm/sec by tcdi). * transfusion within 30 days prior to signing the icf exclusion criteria for part d only: * body weight \<5 kg for 1 month prior to the screening visit and at the screening visit.
sx ella esophageal degradable bd stent system

Conditions: Benign Esophageal Lesions

Summary: the sx-ella stent esophageal degradable bd (bd stent) is designed for dilation of benign esophageal lesions, namely: (1) stenosis (peptic, anastomotic or caustic) refractory to standard therapy, (2) achalasia refractory to standard therapy.


Eligibility criteria:
inclusion criteria: * a recurrent benign esophageal stricture due to all causes (surgery, radiation therapy, corrosive ingestion, peptic injury, pdt, or other ablative therapy) exclusion criteria: * patient \< 18 years old * patient is unwilling or unable to sign and date the informed consent * patient is unwilling or unable to comply with the follow-up schedule * patient is pregnant, breast-feeding, or planning to become pregnant in the next 12 months * patient is simultaneously participating in another drug or device study or the patient has completed the follow-up phase for the primary objective of any previous study less than 30 days prior to enrollment in this study * patient with a life expectancy \< 12 months

Keywords: esophageal stenosis esopageal strictures esophageal dysphagia
adipose tissue cellular response to exercise in healthy humans

Conditions: Metabolic Disease; Adipose Tissue

Summary: the purpose of this study is to measure the effects of a single session of exercise on changes in the cellular composition of the body fat of humans.

fat tissue is far more than just a place where humans store body fat. fat tissue contains many different types of cells, such as immune cells, endothelial cells, and fat precursor cells. differences or changes in the number of immune cells, endothelial cells, and fat precursor cells in fat tissue can have a great impact on metabolic health. the abundance of all immune cells, endothelial cells, and fat precursor cell types are known to change when a person loses or gains weight. for example, the abundance of inflammatory cells is often found to decrease markedly with weight loss - and this change has been linked to the profound improvements in metabolic health that occur with weight loss. in contrast, the effects of exercise on immune cells, endothelial cells, and fat precursor cells in fat tissue is not known. determining the effects of exercise on changes in the cellular composition within fat tissue will provide important information for optimizing lifestyle interventions aimed at improving metabolic health.

Eligibility criteria:
inclusion criteria: * age: 18-40 * body mass index: 20-27 kg/m2 * regular exercise (less than or equal to 3 days/week of aerobic exercise; 30-60 minutes/session at moderate and vigorous intensities) * women must have regularly occurring menses and must be premenopausal exclusion criteria: * blood pressure greater than 140/90 mm hg * pregnant or lactating * evidence/history of cardiovascular or metabolic disease * medications known to affect lipid or glucose metabolism, or inflammation

Keywords: exercise
surgical pleth index (spi) versus standard clinical approach analgesia

Conditions: Anesthesia; Pain; Surgery

Summary: the study is aimed at confronting a surgical pleth index based protocol for intraoperative analgesia in a desflurane based general anesthesia for thyroidectomy, versus a standard clinical approach. a reduction in analgesic consumption and improvement in hemodynamics are expected.


Eligibility criteria:
inclusion criteria: * 18\<age\<80 years * american society of anesthesiology (asa) physical status i -ii * 6 hrs fasting exclusion criteria: * arrhythmia or pacemaker * central or peripheral nervous system or muscular disease * drugs active on autonomous nervous system (eg clonidine) * obesity (bmi \>35) * chronic pain * addictions or central nervous acting drugs use * hypertension (if not treated) * connective tissue disease * pregnancy * allergy or hypersensitivity to study drugs * qt prolongation * absence of inclusion criteria

Keywords: spi remifentanil target controlled infusion
the effect of intelligent exercise and ergonomic recommendations on surgeon musculoskeletal discomfort

Conditions: Occupational Injuries; Occupational Exposure

Summary: the goal of this clinical trial is to investigate the effects of intelligent physical exercise training (ipet) and ergonomic recommendations on musculoskeletal pain among abdominal and pelvic surgeons. the main question it aims to answer is: • is ipet superior to ergonomic recommendations in rehabilitating or preventing musculoskeletal pain? 12 weeks ahead of trial start, all participants will be familiarized with ergonomic principles in the operating room. in the 20-week trial, the control group is asked to resume practicing and applying the ergonomic principles when they operate. in addition to applying the ergonomic principles, the intervention group will be asked to perform 50 min. per week of individually tailored physical exercise training. the program is delivered via an application (app).

pre-intervention the three months leading up to the trial start, all participants are introduced to up-to-date ergonomic recommendations. the ergonomic recommendations are informed by general ergonomic recommendations from the danish working environment authority, a systematic literature review on the effect of ergonomic interventions applied in the or (ref and general ergonomic guidelines) and include two recommendations: 1) performing intra-operative microbreaks, and 2) knowledge of ergonomic work posture in the or. interventionintelligent exercise app + ergonomic recommendations the duration of the ergonomic recommendations launch period is three months after which consenting participants will be randomized to either the control group or the intervention group. the control group will be encouraged to continue to apply the up-to-date ergonomic recommendations to their or practice, this will act as usual care. in addition to the usual care, the intervention group will be prescribed individualized physical exercise training (ipet). the ipet is 50 min of tailored physical exercise per week, that is designed by an algorithm that uses the information (demographics, self-reported health, musculoskeletal pain and its location) the individual enters in the app (ref). the 50 min. of total ipet per week can be performed in one session or divided into shorter sessions two-five sessions with the same effect (ref). the ipet will be delivered through the participants' mobile phone via a mobile application (app) that requires a unique code assigned for each participant. each participant's exercise training program is different because it is composed of the input provided by the participant. thus, as the participants experience progress (or deterioration) in their physical capacity during the study, the program will change accordingly.

Eligibility criteria:
inclusion criteria: * surgeon in gynecologic-, urologic, colorectal or abdominal surgery * performs an average of four hours of surgery per week exclusion criteria: * own physician has advised against performing physical exercise training

Keywords: ergonomics physical exercise training prevention rehabilitation microbreaks surgeons
safety and efficacy of agn-199201 and agn-190584 in patients with presbyopia

Conditions: Presbyopia

Summary: a study to evaluate the safety and efficacy of agn-199201 alone, agn-190584 alone and concurrent use of agn-199201 and agn-190584 in patients with presbyopia (inability to focus for near vision).


Eligibility criteria:
inclusion criteria: -presbyopia in each eye that impacts daily activities. exclusion criteria: * use of any topical ophthalmic medications, including artificial tears * contact lens use in either eye within 14 days or planned use during the study * history of eye surgery * diagnosis of any type of glaucoma or ocular hypertension
safety and feasibility study of enhanced recovery in pancreaticoduodenectomy

Conditions: Pancreatic Neoplasms

Summary: the purpose of this study is to assess the adherence to an enhanced recovery after surgery (eras) pathway and the impact of the eras protocol on postoperative short-term outcome in patients undergoing pancreaticoduodenectomy (pd).

a specific enhanced recovery after surgery (eras) protocol has been applied since october 2010 in consecutive patients undergoing pancreaticoduodenectomy (pd) in a high volume institution. patient compliance for each item has been assessed. each eras patient was matched with a patient who received standard perioperative care. match criteria were age, gender, malignant / benign disease, and pd prognostic score.

Eligibility criteria:
inclusion criteria: * all patients undergoing elective pancreaticoduodenectomy exclusion criteria: * intraoperative detection of metastatic disease (non-operability)
initiation of insulin aspart in type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this trial is to investigate if using insulin aspart as start therapy will improve the efficacy on daytime blood glucose cycle profile in subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes for at least 3 years * hba1c greater than 8.0% * body mass index (bmi) below 40.0 kg/m2 * inadequate treatment with diet and oads * never received treatment with insulin exclusion criteria: * type 1 diabetes * known or suspected allergy to investigational product